Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine Continuation vs Dose Reduction for Post-Operative Pain
NCT04981678Phase 4Terminated
- Sponsor
- MaineHealth
- Start
- Jan 2022
- Primary completion
- Sep 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of buprenorphine in opioid use disorder (OUD) and postoperative pain (2 arms), sponsored by MaineHealth. Primary endpoint: Post-operative Pain Scores. Started Jan 2022; status: terminated.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)postoperative pain
Beyond the preview
Go deeper on NCT04981678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04981678.